Media headlines about Durect (NASDAQ:DRRX) have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Durect earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 45.9658271870473 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Have Sufficient Potential Left To Grow? DURECT Corporation (DRRX), Oil States International, Inc. (OIS) (nmsunews.com)
- Traders Performance Review: DURECT Corporation (DRRX) (mostvolatilestocks.com)
- Analyzing Oramed Pharmaceuticals (ORMP) and Durect (DRRX) (americanbankingnews.com)
- DURECT Corporation (DRRX) In Active Momentum Stock along Profitability Facts (investingbizz.com)
- Analysts’ Activity: Durect Corporation (DRRX) and Trevena Inc (TRVN) (postregistrar.com)
NASDAQ DRRX traded up $0.09 during trading on Thursday, hitting $2.37. 1,575,836 shares of the company’s stock were exchanged, compared to its average volume of 965,781. The company has a current ratio of 2.87, a quick ratio of 2.67 and a debt-to-equity ratio of 0.59. The company has a market cap of $345.01, a price-to-earnings ratio of -79.00 and a beta of 1.05. Durect has a fifty-two week low of $0.74 and a fifty-two week high of $2.40.
Several equities research analysts recently weighed in on the stock. BidaskClub raised shares of Durect from a “hold” rating to a “buy” rating in a research report on Saturday, March 10th. ValuEngine raised shares of Durect from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th. Finally, HC Wainwright raised Durect from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $1.50 to $3.50 in a research note on Tuesday, March 6th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. Durect has a consensus rating of “Buy” and a consensus price target of $2.83.
WARNING: This report was reported by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://baseballnewssource.com/2018/04/05/durect-drrx-given-daily-news-impact-score-of-0-21/2028450.html.
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for Durect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Durect and related companies with MarketBeat.com's FREE daily email newsletter.